IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Recurrent T-Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 89/ 100
Competitive context
84 Active assets in the Recurrent T-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine GC Cell Corporation | Phase 2 | BBB |
Brentuximab Vedotin Yale University | Phase 4 | BBB |
cc-5013 Samsung Medical Center | Phase 2 | BB |
Cyclophosphamide GC Cell Corporation | Phase 3 | BB |
TACROLIMUS M.D. Anderson Cancer Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →